HealthTree News

HealthTree News is a place to learn all about your disease in easy-to-understand language. The site features news articles, patient stories, basics articles, and clinical trial updates with new content every week.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

$Latest in Relapsed/Refractory Amyloidosis Research: Early Results of CAR-T and Bispecific Antibody Clinical Trials$

Jul. 21, 2025

Latest in Relapsed/Refractory Amyloidosis Research: Early Results of CAR-T and Bispecific Antibody Clinical Trials

$Belantamab Combination May Offer an Alternative to CAR-T for Relapsed/Refractory Myeloma$

Jul. 17, 2025

Belantamab Combination May Offer an Alternative to CAR-T for Relapsed/Refractory Myeloma

Jul. 17, 2025

FDA Advisory Committee Rejects Blenrep Combo Therapies—But a Positive Vote is Possible for Myeloma Patients Seeking New Options

Jul. 07, 2025

HealthTree NYC Tour: Experts at Mount Sinai Share the Latest in Myeloma

Jul. 07, 2025

Improved Outcomes with Daratumumab Quadruplet Therapy in Newly Diagnosed Multiple Myeloma

Jul. 02, 2025

FDA Determines CAR-T Can Be Safely Given Without Risk Evaluation and Mitigation Strategies (REMS)

$Linvoseltamab (Lynozyfic) Is Now FDA-approved for Relapsed/Refractory Myeloma$

Jul. 02, 2025

Linvoseltamab (Lynozyfic) Is Now FDA-approved for Relapsed/Refractory Myeloma

Jul. 01, 2025

Crucial Lab Tests For Chronic Kidney Disease

Jul. 01, 2025

New Way to Engineer CAR T-Cells Could Make it More Accessible

$Cilta-cel CAR T-cell Therapy: Unprecedented Long-Term Outcomes in Relapsed and Refractory Myeloma$

Jun. 23, 2025

Cilta-cel CAR T-cell Therapy: Unprecedented Long-Term Outcomes in Relapsed and Refractory Myeloma

Jun. 23, 2025

The Impact of Income and Location in Myeloma Patients’ Outcomes

Jun. 19, 2025

Accessing Specialized Care Centers Can Help Reduce Health Disparities for People with Multiple Myeloma

Treatment Advances

Latest in Relapsed/Refractory Amyloidosis Research: Early Results of CAR-T and Bispecific Antibody Clinical Trials

FDA Advisory Committee Rejects Blenrep Combo Therapies—But a Positive Vote is Possible for Myeloma Patients Seeking New Options

Improved Outcomes with Daratumumab Quadruplet Therapy in Newly Diagnosed Multiple Myeloma

FDA Determines CAR-T Can Be Safely Given Without Risk Evaluation and Mitigation Strategies (REMS)

Linvoseltamab (Lynozyfic) Is Now FDA-approved for Relapsed/Refractory Myeloma

New Way to Engineer CAR T-Cells Could Make it More Accessible

Core Education

Crucial Lab Tests For Chronic Kidney Disease

New Guidelines Define High-Risk Myeloma with Genetics in Mind

What Are Natural Ways To Reduce Creatinine Levels?

What Is APOL1 And How Does It Affect Kidney Disease?

How Are Steroids Used in Blood Cancer Treatment?

Zometa or Xgeva: Tailoring Bone Therapy in Multiple Myeloma

Upcoming Events

Discover Cure Hub with the GW Cancer Center Leukemia and Lymphoma Support Group

Jul 22 / 11:00 EDT

HealthTree Connect to Cures in Harrisonburg, VA – Connect With Other Patients (In-Person Event)

Jul 26 / 10:00 EDT

Can You Stop Myeloma Treatment and Still Stay in Remission?

Jul 29 / 13:00 EDT

Patient Stories

Juliet Robertson’s Poetry on Living with AML Stronger Together - Luis and Paola's Journey with Multiple Myeloma Redefining Patient Evidence: Giving Myeloma Patients a True Voice

HealthTree Research

HealthTree Research: Helping Myeloma Patients Match Clinical Trials With AI Myeloma Pain Relief: What Patients Really Think About Opioids Understanding Shared Decision-Making in Relapsed/Refractory Myeloma

Conferences

Belantamab Combination May Offer an Alternative to CAR-T for Relapsed/Refractory Myeloma The Impact of Income and Location in Myeloma Patients’ Outcomes Accessing Specialized Care Centers Can Help Reduce Health Disparities for People with Multiple Myeloma

Clinical Trials

New Trispecific Antibody JNJ-5322 Shows Strong Results in Relapsed/Refractory Myeloma Moving Belantamab Mafodotin to Newly Diagnosed Myeloma? Targeting ROR1 in Blood Cancers

HealthTree Press

The Importance of Using Newer Myeloma Treatments Like CAR T-cell Therapy Closing the Gaps in Multiple Myeloma Care for African Americans HealthTree Foundation CEO Jenny Ahlstrom Honored as 2025 Remarkable Women Honoree by ABC4 Utah

HealthTree Programs

HealthTree NYC Tour: Experts at Mount Sinai Share the Latest in Myeloma Honoring Freedom, Advancing Health: Why Juneteenth Matters to the Black Blood Cancer Community Optimizing Care for Frailty in Myeloma Patients

Thanks to our sponsors:

All HealthTree resources available anywhere, anytime

Download our App

Download our App

Charity Navigator

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Tax ID 45-5354811

HealthTree News

Recent Articles

Honoring Freedom, Advancing Health: Why Juneteenth Matters to the Black Blood Cancer Community

Dual Antibody Therapy for Extramedullary Myeloma

New Trispecific Antibody JNJ-5322 Shows Strong Results in Relapsed/Refractory Myeloma

Treatment Advances

Core Education

Trending Articles

Belantamab Combination May Offer an Alternative to CAR-T for Relapsed/Refractory Myeloma

FDA Advisory Committee Rejects Blenrep Combo Therapies—But a Positive Vote is Possible for Myeloma Patients Seeking New Options

New Way to Engineer CAR T-Cells Could Make it More Accessible

Improved Outcomes with Daratumumab Quadruplet Therapy in Newly Diagnosed Multiple Myeloma

Understanding Shared Decision-Making in Relapsed/Refractory Myeloma

Upcoming Events

Discover Cure Hub with the GW Cancer Center Leukemia and Lymphoma Support Group

HealthTree Connect to Cures in Harrisonburg, VA – Connect With Other Patients (In-Person Event)

Can You Stop Myeloma Treatment and Still Stay in Remission?

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info

Follow Us

HealthTree News

Recent Articles

Honoring Freedom, Advancing Health: Why Juneteenth Matters to the Black Blood Cancer Community

Dual Antibody Therapy for Extramedullary Myeloma

New Trispecific Antibody JNJ-5322 Shows Strong Results in Relapsed/Refractory Myeloma

Treatment Advances

Core Education

Trending Articles

Belantamab Combination May Offer an Alternative to CAR-T for Relapsed/Refractory Myeloma

FDA Advisory Committee Rejects Blenrep Combo Therapies—But a Positive Vote is Possible for Myeloma Patients Seeking New Options

New Way to Engineer CAR T-Cells Could Make it More Accessible

Improved Outcomes with Daratumumab Quadruplet Therapy in Newly Diagnosed Multiple Myeloma

Understanding Shared Decision-Making in Relapsed/Refractory Myeloma

Upcoming Events

Discover Cure Hub with the GW Cancer Center Leukemia and Lymphoma Support Group

HealthTree Connect to Cures in Harrisonburg, VA – Connect With Other Patients (In-Person Event)

Can You Stop Myeloma Treatment and Still Stay in Remission?

Get the Latest Multiple Myeloma Updates, Delivered to You.

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info

Follow Us